Emmaus Life Sciences Sickle Cell Treatment Receives Positive Opinion on Pediatric Investigation Plan from European Medicines AgencyDecember 21, 2017 Read More
Emmaus Medical, Inc. Announces Availability of Endari™ for Treatment of Sickle Cell DiseaseDecember 11, 2017 Read More
Emmaus Life Sciences, Inc. to Present Results of Phase 3 Study of EndariTM (L-glutamine oral powder) at 59th American Society of Hematology Annual MeetingNovember 28, 2017 Read More
The U.S. Food & Drug Administration Approves Endari™ (L-glutamine oral powder), the First and Only Treatment for Sickle Cell Disease in Pediatric Patients and First in Nearly 20 Years for AdultsJuly 07, 2017 Read More
